Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

VIRX

Viracta Therapeutics Inc

Apr 19 • 04:00PM ET

0.8567

Dollar change -0.0523
Percentage change -5.75	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.32	Insider Own	30.00%	Shs Outstand	39.09M	Perf Week	-25.50%
Market Cap	33.64M	Forward P/E	-	EPS next Y	-1.12	Insider Trans	0.79%	Shs Float	27.49M	Perf Month	-24.19%
Income	-50.97M	PEG	-	EPS next Q	-0.35	Inst Own	24.47%	Short Float	2.36%	Perf Quarter	67.65%
Sales	0.00M	P/S	-	EPS this Y	11.93%	Inst Trans	3.12%	Short Ratio	5.62	Perf Half Y	22.21%
Book/sh	0.33	P/B	2.60	EPS next Y	3.66%	ROA	-66.76%	Short Interest	0.65M	Perf Year	-35.10%
Cash/sh	1.37	P/C	0.63	EPS next 5Y	-	ROE	-128.34%	52W Range	0.43 - 2.38	Perf YTD	50.30%
Dividend Est.	-	P/FCF	-	EPS past 5Y	44.96%	ROI	-278.22%	52W High	-64.00%	Beta	0.92
Dividend TTM	-	Quick Ratio	1.43	Sales past 5Y	134.94%	Gross Margin	-	52W Low	99.23%	ATR (14)	0.14
Dividend Ex-Date	-	Current Ratio	1.43	EPS Y/Y TTM	-1.30%	Oper. Margin	0.00%	RSI (14)	44.21	Volatility	25.04% 13.83%
Employees	40	Debt/Eq	1.40	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	7.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-31.69%	Payout	-	Rel Volume	0.46	Prev Close	0.91
Sales Surprise	-	EPS Surprise	-12.90%	Sales Q/Q	-	Earnings	Mar 07 AMC	Avg Volume	115.37K	Price	0.86
SMA20	-16.66%	SMA50	-4.32%	SMA200	-5.67%	Trades		Volume	52,613	Change	-5.75%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-01-22	Initiated	RBC Capital Mkts	Outperform	$10
May-03-21	Initiated	H.C. Wainwright	Buy	$35
Apr-26-21	Initiated	SVB Leerink	Outperform	$18
Mar-25-21	Initiated	Evercore ISI	Outperform	$45

Apr-15-24 08:00AM	Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma (GlobeNewswire) -32.17%
Apr-01-24 08:30AM	Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan (GlobeNewswire) +8.82%
Mar-08-24 08:51AM	VIRX Stock Earnings: Viracta Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
Mar-07-24 04:05PM	Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire) -11.92%
Feb-29-24 08:00AM	Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial (GlobeNewswire) -8.43%
04:05PM	Loading…
Feb-06-24 04:05PM	Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-17-24 08:00AM	INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors (GlobeNewswire)
Jan-04-24 08:00AM	Viracta Therapeutics Provides Clinical Update and Outlook for 2024 (GlobeNewswire)
Dec-12-23 08:00AM	Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma (GlobeNewswire) -6.28%
Dec-04-23 08:30AM	Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels (GlobeNewswire)
Nov-09-23 08:30AM	Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -14.70%
Nov-07-23 04:15PM	Viracta Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-04-23 07:00AM	Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers (GlobeNewswire) -10.68%
Sep-05-23 09:00AM	Viracta Therapeutics to Host R&D Day on October 4, 2023 (GlobeNewswire)
Aug-18-23 04:05PM	Viracta Therapeutics Announces New Employment Inducement Grant (GlobeNewswire)
08:00AM	Loading…
Aug-14-23 08:00AM	Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-08-23 08:30AM	Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma (GlobeNewswire)
Aug-07-23 07:30AM	Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer (GlobeNewswire) -6.67%
Jun-28-23 08:00AM	Viracta Therapeutics Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL) (GlobeNewswire) +5.59%
May-31-23 04:15PM	Viracta Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-17-23 09:50AM	2 Strong Buy Penny Stocks With Over 400% Upside on the Horizon (TipRanks) +37.35%
May-11-23 04:05PM	Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-08-23 04:05PM	Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates (GlobeNewswire) -11.00%
May-02-23 04:05PM	Viracta Therapeutics Announces Departure of Chief Medical Officer (GlobeNewswire)
Apr-19-23 04:30PM	Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days (GlobeNewswire)
Mar-13-23 04:05PM	Viracta Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
Mar-08-23 04:05PM	Viracta Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare Conference (GlobeNewswire)
Feb-07-23 04:05PM	Viracta Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-19-23 08:30AM	Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission to Nana-val for the Treatment of Diffuse Large B-cell Lymphoma (GlobeNewswire)
Jan-08-23 01:00PM	Viracta Therapeutics Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives (GlobeNewswire)
06:10PM	Loading…
Nov-30-22 06:10PM	Viracta Therapeutics Announces Preliminary Dose-Ranging Data from the Phase 1b/2 Trial of Nana-val in Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors at the ESMO Immuno-Oncology Congress (GlobeNewswire)
Nov-21-22 05:08PM	Viracta Therapeutics Announces New Employment Inducement Grant (GlobeNewswire) -6.18%
Nov-14-22 04:41PM	Viracta Therapeutics Announces New Employment Inducement Grant (GlobeNewswire)
Nov-10-22 04:05PM	Viracta Therapeutics Reports Third Quarter 2022 Financial Results and Provides Updates on Clinical Programs (GlobeNewswire)
Nov-02-22 04:05PM	Viracta Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Sep-19-22 04:30PM	Viracta Therapeutics Announces New Employment Inducement Grant (GlobeNewswire) -8.44%
08:00AM	Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's Strategic Development and Growth (PR Newswire)
Sep-07-22 09:00AM	Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission for Nana-val for the Treatment of Peripheral T-cell Lymphoma (PR Newswire) +11.86%
Aug-16-22 04:15PM	Viracta Therapeutics Chief Scientific Officer, Dr. Ayman Elguindy, Elected to the Governing Board of the International Association for Research on Epstein-Barr Virus and Associated Diseases (PR Newswire) -7.24%
Aug-11-22 09:00AM	Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors (PR Newswire) +9.21%
Aug-09-22 08:30AM	Viracta Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates (PR Newswire) -12.15%
Aug-01-22 08:19AM	What Kind Of Shareholders Hold The Majority In Viracta Therapeutics, Inc.'s (NASDAQ:VIRX) Shares? (Simply Wall St.)
Jun-13-22 04:15PM	Viracta Therapeutics President and Chief Executive Officer Dr. Ivor Royston Receives the Science History Institute's Biotechnology Heritage Award (PR Newswire) -7.30%
Jun-02-22 08:30AM	Viracta Therapeutics Provides an Update on the Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and Announces Upcoming Poster Presentation at the ASCO Annual Meeting (PR Newswire)
Jun-01-22 04:15PM	Viracta Therapeutics to Present at the Jefferies Healthcare Conference (PR Newswire)
May-23-22 08:00AM	Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman (GlobeNewswire)
May-13-22 04:05PM	Viracta Therapeutics Announces New Employment Inducement Grant (PR Newswire)
May-11-22 04:05PM	Viracta Therapeutics to Present at Upcoming May Investor Conferences (PR Newswire) -11.69%
May-10-22 04:05PM	Viracta Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates (PR Newswire)
Apr-20-22 11:58AM	Viracta Therapeutics to Host Key Opinion Leader Webinar on Nana-val for the Treatment of Advanced Epstein-Barr Virus-Positive Solid Tumors (PR Newswire)
Apr-07-22 10:13AM	Viracta Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-18-22 04:10PM	Viracta Therapeutics Announces New Employment Inducement Grant (PR Newswire)
Mar-09-22 04:30PM	Viracta Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference (PR Newswire) +5.76%
Feb-22-22 11:35AM	What Type Of Shareholders Own The Most Number of Viracta Therapeutics, Inc. (NASDAQ:VIRX) Shares? (Simply Wall St.)
Feb-10-22 09:00AM	Viracta Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference (PR Newswire) +9.12%
Feb-08-22 09:48AM	2 Strong Buy Penny Stocks That Could Rally to $10 (or More) (TipRanks) +8.04%
Jan-31-22 08:30AM	Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid Tumors (PR Newswire) +11.20%
Jan-04-22 09:00AM	Viracta Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference (PR Newswire) -6.39%
Dec-16-21 08:30AM	Viracta Therapeutics to be Added to the Nasdaq Biotechnology Index (PR Newswire)
Dec-13-21 07:15PM	Viracta Therapeutics Presents Preclinical Vecabrutinib Data in Oral and Poster Presentations at ASH 2021 (PR Newswire) -9.05%
11:30AM	Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021 (PR Newswire)
Nov-29-21 08:00AM	Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for its All-Oral Combination of Nanatinostat and Valganciclovir (Nana-val) for the Treatment of Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma (PR Newswire) -5.58%
Nov-10-21 08:00AM	Viracta Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update (PR Newswire)
Nov-05-21 09:00AM	Viracta Therapeutics Secures $50 Million Credit Facility from Silicon Valley Bank and Oxford Finance (PR Newswire)
Nov-04-21 09:00AM	Viracta Therapeutics Announces Upcoming Oral and Poster Presentations at the 2021 American Society of Hematology Annual Meeting (PR Newswire)
Nov-01-21 04:05PM	Viracta Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
Oct-06-21 08:00AM	Viracta Therapeutics Initiates Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors (PR Newswire)
Sep-07-21 08:00AM	Viracta Therapeutics to Present at Upcoming Investor Conferences in September (PR Newswire)
Aug-23-21 08:00AM	Viracta Therapeutics Reacquires Exclusive Development and Commercialization Rights for its All-Oral Combination Therapy in China (PR Newswire) +6.95%
Aug-16-21 08:00AM	Viracta Therapeutics Announces the Appointment of Flavia Borellini, Ph.D., and Jane F. Barlow, M.D., MPH, MBA, to its Board of Directors (PR Newswire) -10.43%
Aug-12-21 08:00AM	Viracta Therapeutics Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates (PR Newswire)
Jul-21-21 08:00AM	Viracta Therapeutics Announces FDA Clearance of IND Application for Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors (PR Newswire)
Jul-06-21 08:00AM	Viracta Therapeutics Announces the Appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer and Key Additions to Management Team (PR Newswire) -6.02%
Jun-28-21 08:00AM	Viracta Therapeutics Announces its Addition to the Russell 2000® Index and other FTSE Russell Indexes (PR Newswire)
Jun-01-21 08:00AM	Viracta Therapeutics Announces the Initiation of NAVAL-1, a Global Pivotal Trial for the Treatment of Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma (PR Newswire)
May-25-21 07:46AM	What Kind Of Shareholders Hold The Majority In Viracta Therapeutics, Inc.'s (NASDAQ:VIRX) Shares? (Simply Wall St.) +6.23%
May-18-21 04:05PM	Viracta Therapeutics to Host Key Opinion Leader Webinar (PR Newswire) +6.46%
May-12-21 04:05PM	Viracta Therapeutics Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates (PR Newswire)
Apr-29-21 06:01AM	Analysts Bet on These 2 Biotech Stocks; See Over 50% Upside Potential (TipRanks)
Apr-08-21 08:00AM	Viracta Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-23-21 08:00AM	Viracta and XOMA Announce Multi-License Milestone and Royalty Monetization Transaction (PR Newswire) -5.09%
Mar-11-21 08:00AM	Viracta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference (PR Newswire) +7.73%
Mar-04-21 08:00AM	Viracta Therapeutics Strengthens Company Leadership with New Appointments to the Board of Directors and Management Team (PR Newswire) -18.30%
Mar-03-21 08:00AM	Viracta Therapeutics to Participate at H.C. Wainwright Global Life Sciences Conference (PR Newswire)

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chevallard Daniel R.	CFO and COO	Feb 27 '24	Sale	0.73	3,405	2,493	102,306	Feb 27 07:54 PM
Chevallard Daniel R.	CFO and COO	Feb 25 '24	Option Exercise	0.00	6,889	0	105,711	Feb 27 07:54 PM
ROYSTON IVOR	Director	Feb 25 '24	Option Exercise	0.00	25,219	0	764,084	Feb 27 07:58 PM
Pomerantz Roger	Director	Feb 25 '24	Option Exercise	0.00	9,034	0	99,375	Feb 27 07:56 PM
Rothera Mark	President and CEO	Dec 01 '23	Buy	0.49	47,906	23,627	100,000	Dec 04 04:54 PM
Rothera Mark	President and CEO	Nov 30 '23	Buy	0.49	52,094	25,734	52,094	Dec 04 04:54 PM
Chevallard Daniel R.	CFO and COO	Nov 28 '23	Sale	0.50	3,720	1,860	98,822	Nov 28 07:06 PM
Chevallard Daniel R.	CFO and COO	Nov 25 '23	Option Exercise	0.00	6,889	0	102,542	Nov 28 07:06 PM
ROYSTON IVOR	Director	Nov 25 '23	Option Exercise	0.00	25,219	0	738,865	Nov 28 07:03 PM
Pomerantz Roger	Director	Nov 25 '23	Option Exercise	0.00	9,034	0	90,341	Nov 28 07:01 PM
Chevallard Daniel R.	CFO and COO	Aug 28 '23	Sale	1.45	3,512	5,092	95,653	Aug 29 06:47 PM
Chevallard Daniel R.	CFO and COO	Aug 25 '23	Option Exercise	0.00	6,888	0	99,165	Aug 29 06:47 PM
Pomerantz Roger	Director	Aug 25 '23	Option Exercise	0.00	9,034	0	81,307	Aug 29 06:49 PM
ROYSTON IVOR	Director	Aug 25 '23	Option Exercise	0.00	25,219	0	713,646	Aug 29 06:52 PM
Chevallard Daniel R.	CFO and COO	May 25 '23	Option Exercise	0.00	6,889	0	95,912	May 26 07:29 PM
ROYSTON IVOR	Director	May 25 '23	Option Exercise	0.00	25,219	0	688,427	May 26 07:32 PM
Pomerantz Roger	Director	May 25 '23	Option Exercise	0.00	9,035	0	72,273	May 26 07:30 PM
Chevallard Daniel R.	CFO and COO	May 25 '23	Sale	1.42	3,635	5,160	92,277	May 26 07:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VIRX

Viracta Therapeutics Inc

Upgrade your FINVIZ experience